EGFR and neoplasm: The isolated peripheral T cells can be genetically engineered to target several known tumor antigens of HNSCC, including, EGFR, MAGE-A4, MUC1, CD 70, and HER2, and the ACT with these agents has demonstrated a durable clinical response in early clinical studies [163,164,165].